1 | All patients in the study will be treated with ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
2 | Continued Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
3 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | 12件: Acetate Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab, Ponesimod, Rituximab, Teriflunomide | 10件: D01370
D01370
,
D02802
,
D02994
,
D03846
,
D05218
(Name: Ocrelizumab),
D06886
,
D09314
,
D10001
,
D10172
,
D11215
| 7件: CD52 CD52, DHODH, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬 | 31件: , Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬 | 1件: 13 13 |
4 | OCR | - | - | - | - | 1件: 13 13 |
5 | OCRELIZUMAB | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 46, 49 |
6 | Ocrelizumab (CinnaGen, Iran) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
7 | Ocrelizumab (Roche, Switzerland) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
8 | Ocrelizumab / rhuMAb 2H7 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
9 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
10 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
11 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
12 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
13 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
14 | Ocrelizumab 500mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
15 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
16 | Ocrelizumab at home | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
17 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
18 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
19 | Ocrelizumab IV | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
20 | Ocrelizumab SC | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
21 | Ocrelizumabu 200mg | - | - | - | - | 1件: 46 46 |
22 | Ocrelizumabu 50mg | - | - | - | - | 1件: 46 46 |
23 | OCREVUS | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
24 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
25 | OCRH | - | - | - | - | 2件: 75 75, 232 |
26 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 |
27 | Ovine Corticotropin-Releasing Hormone (oCRH) | 2件: Corticorelin Corticorelin, Corticotropin | 2件: D00146
D00146
,
D03905
| 3件: CRHR1 CRHR1, CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
28 | Perfusion of treatment Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
29 | Short-course Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |